MOLECULAR MODELING AND ADMET-GUIDED OPTIMIZATION OF NOVEL ANTIBACTERIAL COMPOUNDS AGAINST DRUG-RESISTANT PATHOGENS

Authors

  • Dr. Oliver T. Bennett Department of Biomedical Sciences, International Center for Drug Research, USA

Keywords:

antibacterial drug discovery; antimicrobial resistance; molecular docking; QSAR; molecular dynamics; ADMET; Gram-negative permeability; drug-resistant pathogens.

Abstract

Antimicrobial resistance has intensified the need for antibacterial agents that combine potent target engagement with the ability to reach bacterial intracellular targets and maintain acceptable pharmacokinetic and safety profiles. This article evaluates an integrated molecular-modeling and ADMET-guided strategy for the prioritization and optimization of novel antibacterial compounds against drug-resistant pathogens. A structured narrative review of representative international literature was organized around target selection, quantitative structure-activity relationship (QSAR) modeling, molecular docking, molecular dynamics (MD), bacterial permeability and efflux considerations, and in silico absorption, distribution, metabolism, excretion and toxicity (ADMET) assessment. The synthesis shows that target affinity alone is an insufficient optimization objective, particularly for Gram-negative pathogens, where outer-membrane penetration, porin passage and active efflux can dominate whole-cell activity. Modern workflows therefore benefit from sequential filtering that combines structure-based binding models with physicochemical constraints, bacterial accumulation rules and mammalian safety prediction. Deep-learning studies further demonstrate that large chemical spaces can be searched for structurally novel antibacterial scaffolds, but explainability and experimental validation remain essential. An integrated decision framework is proposed in which molecular docking and QSAR identify potency-driving features, MD tests persistence of key interactions, and SwissADME, pkCSM, ADMETlab and toxicity models expose development liabilities before synthesis. The approach can reduce false-positive prioritization and support the selection of experimentally testable leads, although computational predictions cannot replace microbiological susceptibility, cytotoxicity, resistance-frequency and in vivo validation.

References

1.Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325), 629-655. https://doi.org/10.1016/S0140-6736(21)02724-0

2.Brown, E. D., & Wright, G. D. (2016). Antibacterial drug discovery in the resistance era. Nature, 529(7586), 336-343. https://doi.org/10.1038/nature17042

3.Lewis, K. (2013). Platforms for antibiotic discovery. Nature Reviews Drug Discovery, 12(5), 371-387. https://doi.org/10.1038/nrd3975

4.Richter, M. F., Drown, B. S., Riley, A. P., Garcia, A., Shirai, T., Svec, R. L., & Hergenrother, P. J. (2017). Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature, 545, 299-304. https://doi.org/10.1038/nature22308

5.Masi, M., Refregiers, M., Pos, K. M., & Pages, J.-M. (2017). Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria. Nature Microbiology, 2, 17001.

6.Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., et al. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688-702.e13. https://doi.org/10.1016/j.cell.2020.01.021

7.Wong, F., Zheng, E. J., Valeri, J. A., Donghia, N. M., Anahtar, M. N., Omori, S., et al. (2024). Discovery of a structural class of antibiotics with explainable deep learning. Nature, 626(7997), 177-185. https://doi.org/10.1038/s41586-023-06887-8

8.Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021). AutoDock Vina 1.2.0: New docking methods, expanded force field, and Python bindings. Journal of Chemical Information and Modeling, 61(8), 3891-3898. https://doi.org/10.1021/acs.jcim.1c00203

9.Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., et al. (2014). QSAR modeling: Where have you been? Where are you going to? Journal of Medicinal Chemistry, 57(12), 4977-5010. https://doi.org/10.1021/jm4004285

10.Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717

11.Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066-4072. https://doi.org/10.1021/acs.jmedchem.5b00104

12.Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., et al. (2021). ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research, 49(W1), W5-W14. https://doi.org/10.1093/nar/gkab255

13.Abraham, M. J., Murtola, T., Schulz, R., Pall, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2, 19-25. https://doi.org/10.1016/j.softx.2015.06.001

14.Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018). ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 46(W1), W257-W263. https://doi.org/10.1093/nar/gky318

15.Seiple, I. B., Zhang, Z., Jakubec, P., Langlois-Mercier, A., Wright, P. M., Hog, D. T., et al. (2016). A platform for the discovery of new macrolide antibiotics. Nature, 533(7603), 338-345. https://doi.org/10.1038/nature17967

Published

2026-09-20